Aldeyra Therapeutics, Inc. (ALDX)

Sentiment-Signal

15,3

Stark Bearisch

Composite Score (0–100)

Insider (25%)

29.8

1 Insider, 98K $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
17.04.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C

Stammdaten

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Unternehmen & Branche

Name	Aldeyra Therapeutics, Inc.
Ticker	ALDX
CIK	0001341235
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	90,0 Mio. USD
Beta	1,33
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	-33,846,661	-0.56	72,059,317	44,250,390
2025-09-30	10-Q	-7,688,341	-0.13	77,801,012	49,244,543
2025-06-30	10-Q	-9,767,312	-0.16	84,962,888	55,288,142
2025-03-31	10-Q	-9,929,501	-0.17	93,195,717	63,598,577
2024-12-31	10-K	-55,851,444	-0.94	104,606,694	71,004,871
2024-09-30	10-Q	-15,112,983	-0.25	117,319,352	85,095,704
2024-06-30	10-Q	-16,847,572	-0.28	126,043,834	98,310,339
2024-03-31	10-Q	-8,082,122	-0.14	141,301,892	113,419,441
2023-12-31	10-K	-37,542,510	-0.64	148,326,911	119,795,030
2023-09-30	10-Q	-8,186,871	-0.14	147,282,247	123,007,739
2023-06-30	10-Q	-8,986,998	-0.15	155,616,350	129,883,199
2023-03-31	10-Q	-15,615,679	-0.27	168,218,792	137,243,213
2022-12-31	10-K	-62,024,636	-1.06	181,291,657	151,008,029
2022-09-30	10-Q	-14,553,231	-0.25	189,691,725	162,193,649
2022-06-30	10-Q	-17,780,951	-0.30	201,015,324	174,029,008
2022-03-31	10-Q	-16,788,292	-0.29	222,692,981	190,688,722
2021-12-31	10-K	-57,776,274	-1.07	233,137,120	205,735,523
2021-09-30	10-Q	-15,794,955	-0.27	247,217,570	219,669,902
2021-06-30	10-Q	-14,936,910	-0.28	256,427,212	233,679,945
2021-03-31	10-Q	-11,289,862		147,306,100	126,074,472

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-19	DOUGLAS RICHARD	Director	Open Market Purchase	70,000	1.40	98,000.00	+168,9%
2026-03-18	Alfieri Michael	Officer, Principal Financial Officer	Open Market Purchase	5,000	1.42	7,100.00	+12,2%
2025-08-13	Alfieri Michael	Officer, Principal Financial Officer	Open Market Purchase	2,500	5.30	13,250.00	+22,8%
2025-08-11	Machatha Stephen	Officer, Chief Development Officer	Open Market Sale	-22,073	5.15	-113,713.47	-196,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.